13
Drug Development • This is not for the faint of heart or the poor! • It always takes longer and costs more than projected! • If they tell you they only need another $X million throw them out!

CBI Presentation March 2011

Embed Size (px)

DESCRIPTION

R&D Program Valuation and Prioritization - Keys to Being a Strategic Business Partner to the R&D Organization

Citation preview

Page 1: CBI Presentation March 2011

Drug Development• This is not for the faint of heart or the

poor!• It always takes longer and costs more

than projected!• If they tell you they only need another

$X million throw them out!

Page 2: CBI Presentation March 2011

Macro Issues

• Funding is difficult to come by• Investors expect results from R&D• Pipe lines have holes• Revenue cliff• Goal approved drug/marketable product

Page 3: CBI Presentation March 2011

Lesson Learned

• Is the Finance role much different in a manufacturing environment than an R&D organization?

• Edgcomb metals Plant manager put his best people on Inventory Management

Page 4: CBI Presentation March 2011

Recommendation #1

• In order to support the R&D project teams as a finance resource and business partner– Put your best finance people on the R&D area• External reporting• Internal reporting

– Increased emphasis– Assist R&D with putting together and accurate projection– Monitor monthly activity

» Actual $ spent plus ESTIMATE to complete = total spend

Page 5: CBI Presentation March 2011

Recommendation #2• Engage with R&D leaders – Finance must attend the project meetings and

issue a report to controller/CFO• Finance understands the big picture as funds move

from R to D to CMC to Regulatory to Marketing• Changes in direction cause changes in spending• When to pull the plug!• Provide real feedback on $ spent

Page 6: CBI Presentation March 2011

Recommendation #3• Finance Department’s role as an advisor to

R&D on business decisions– Cash is limited.– Every project cannot be funded.– Existing projects must be managed• Expectations must be set with respect to cost• “What if” scenarios need to be addressed.

– Additional trials, managing vendors

Page 7: CBI Presentation March 2011

Recommendation #4Enhancing Financial Planning Systems

• Finance must drive the planning process.– Start with excel before moving to complicated

software.– Top down to kick off the process– Bottom up approach to provide a roadmap• Pre-fill the budget amounts to get the process started.

Page 8: CBI Presentation March 2011

Example 1Top Down Approach

Assumption – 2 year’s of Cash on hand

Description $Anidulafungin 10,000,000Dalbavancin 5,000,000Marketing 5,000,000G&A 5,000,000Total 25,000,000

Page 9: CBI Presentation March 2011

Example of bottom up(000’s)

Dalbavancin Q1 Q2 Q3 Q4 Total

Clinical Trial $ 700 $700 $700 $700 $2,800

Toxicology $200 $200 $200 $200 $800

CMC $250 $250 $250 $250 $1,000

Travel $100 $100 $100 $100 $400

$5,000

Page 10: CBI Presentation March 2011

Recommendation #5• Finance must manage the Budget and Forecasting

process– Buckets, Ranges and Cushions – One cost center per project

• Gl accounts – not too many and not to few

– Provide hard copy summary to R & D combined with an end of month meeting to discuss results.

– Rolling forecasts • Monthly preferred • Quarterly at a minimum• Prior year carryovers.

Page 11: CBI Presentation March 2011

Recommendation #6 Assessing the Economics of an R&D

• Engage ex FDA consultants to review:– Preclinical– Clinical– CMC– NDA

• Perform a robust marketing study for the target.– Start with the end in mind.

Page 12: CBI Presentation March 2011

Recommendation #7 Cost Management and Bench Marking

• Cost per patient– How does it compare to other studies?– How does it compare to other companies?

• Bring major vendors into the office quarterly.• Prevent cost over runs before they occur.

Page 13: CBI Presentation March 2011

Recommendation #8 Accounting for Clinical Grants & Internal

Development

• Assign a specific person to monitor– Excel templates.– Time sheets– External review by a third party.